Oral GLP-1 pipeline overview — all agents in development

roxy_nash said:

The version of this that has an answer is narrower than the version being asked.

Adding the part of the answer the thread has not reached. It helps to ask what evidence would change your mind before you look at any. If nothing would, the discussion is not about evidence, and it is better to say so early than to spend nine posts discovering it.

One concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

A narrower follow-up, since the general answer is now clear:

How much of the oral variability is the SNAC absorption window and how much is dose, because the two get conflated constantly?

PharmacoVig_BOS said:

Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a…

I do not accept the framing. The question has been narrowed to the version that has a tidy answer, and the part that was dropped is the part the OP actually asked about.

Closing the loop on my own question.

Resolved, and the thing that resolved it was the least interesting suggestion in the thread. Writing that down for the next person who wants the interesting answer.